The effects of choreito on a model of nocturnal polyuria using Dahl salt‐sensitive rats

Abstract

Objectives This study aimed to determine whether Dahl salt‐sensitive rats fed a high‐salt diet would show features of nocturia due to nocturnal polyuria and to examine the efficacy of choreito (CRT) on nocturnal polyuria. Methods Dahl salt‐sensitive rats were divided into three groups. Group A was fed a 4% salt diet, group B a 2% salt diet, and group C a normal 0.3% salt diet. In groups α and β, other rats were further divided into two groups: The rats in group α were fed a 2% salt plus 3% CRT diet, and those in group β, were fed a 2% salt diet. Each rat was placed in an individual metabolic cage for 24 hours every week for 6 weeks. Water intake, urine production, voiding frequency, and voided volume per micturition were recorded. Results The systolic blood pressure increased in the group fed a 4% salt diet compared to groups fed with a 2% and 0.3% salt diet. The urinary volume was higher in the groups fed with 4% and 2% salt than in the group fed with 0.3% salt. Further, water intake in the group fed a 2% salt plus 3% CRT diet was significantly lower than that in the group fed with a 2% salt diet. Conclusions Dahl salt‐sensitive rats fed a 2% salt diet were candidates for a model of nocturnal polyuria. Using this model, we suggest that CRT reduces water intake in the active phase and contributes to water restriction in the treatment of nocturnal polyuria.

Choreito, a Kampo medicine attenuates detrusor overactivity and bladder pain symptoms in rat tranilast‐induced interstitial cystitis/bladder pain syndrome‐like model

“…A recent paper suggests that CRT attenuates detrusor overactivity induced by chemical urothelial irritation, and its therapeutic effects include the inhibition of urothelial damage, regulation of excessive blood flow, and reduction in edematous change 16 . In the study of nocturnal polyuria, water utilization effect of CRT reported that may contribute to urination at nocturnal time by reduce water intake in the active time on the Dahl‐sensitive rats 17 . This study aimed to investigate the therapeutic effects of CRT on the IC/BPS‐like model.…”

“…16 In the study of nocturnal polyuria, water utilization effect of CRT reported that may contribute to urination at nocturnal time by reduce water intake in the active time on the Dahl-sensitive rats. 17 This study aimed to investigate the therapeutic effects of CRT on the IC/ BPS-like model. Chronic bladder inflammation triggers the release of algesic mediators, prostaglandins, serotonin, histamine, and bradykinin.…”

Prescription of Choreito, a Japanese Kampo Medicine, with Antimicrobials for Treatment of Acute Cystitis: A Retrospective Cohort Study

“…As mentioned above, in Japanese clinical practice, Kampo is widley accepted in daily clinical practice [ 23 , 26 ], and Choreito is widely prescribed for the relief of lower urinary tract symptoms, especially for dysuria, decreased urine output, and dryness of the oral cavity [ 16 , 27 ]. Some constituents of Choreito, such as aluminum silicate hydrate, Alisma rhizome, Polyporus umbellatus sclerotium, and Poria sclerotium, are said to have diuretic effects and improve water imbalance in the body [ 10 ]; however, the biological response of each of these components is not fully understood.…”

“…Choreito is a medicinal herb composed of five aqueous extracts, including aluminum silicate hydrate with silicon dioxide, Alisma rhizome (a rhizome of Alisma orientale Juzepczuk), Polyporus umbellatus sclerotium, Poria sclerotium (a dried sclerotium of Wolfiporia cocos Ryvarden et Gilbertson), and Donkey glue. Several studies have reported supportive data regarding the effects of Choreito on the alleviation of lower urinary tract symptoms in patients who complain of decreased urine volume, dysuria, and oral dryness [ 10 , 11 , 12 , 13 , 14 , 15 , 16 ]. In the context of Kampo medicine, Choreito is clinically considered to “dampen heat” in the lower abdomen, characteristic symptoms of which include dysuria, heat in the lower abdomen, and thirst [ 17 ].…”